Drug Shortage Report for HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
| Report ID | 150232 |
| Drug Identification Number | 02491699 |
| Brand name | HYDROMORPHONE HYDROCHLORIDE INJECTION, USP |
| Common or Proper name | HYDROmorphone Hydrochloride Injection, USP 2 mg/mL SD Vial 1 mL |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | HYDROMORPHONE HYDROCHLORIDE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 1 mL |
| ATC code | N02AA |
| ATC description | OPIOIDS |
| Reason for shortage | Delay in shipping of the drug. |
| Anticipated start date | 2021-12-16 |
| Actual start date | |
| Estimated end date | 2022-01-14 |
| Actual end date | 2022-01-14 |
| Shortage status | Resolved |
| Updated date | 2022-01-17 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a shipping delay, we will be encountering a supply interruption on our HYDROmorphone Hydrochloride Injection, USP 2 mg/mL SD Vial 1 mL effective December 16, 2021 until January 14, 2022. Sandoz is an alternate supplier of HYDROmorphone Hydrochloride Injection, USP and has been informed of our impending supply interruption. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2021-11-30 | English | Compare |
| v2 | 2021-11-30 | French | Compare |
| v3 | 2021-12-17 | English | Compare |
| v4 | 2022-01-17 | English | Compare |
| v5 | 2022-01-17 | French | Compare |
Showing 1 to 5 of 5